FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206479551> ?p ?o ?g. }

• W3206479551 abstract "While several phase III trials have investigated the role of hypofractionated radiotherapy in the definitive treatment of localized prostate cancer, prospective data reporting the outcomes of hypofractionated radiotherapy in the postoperative treatment setting are sparse. Therefore, this study is designed to assess the efficacy and treatment-related toxicity of hypofractionated salvage radiotherapy for the treatment of biochemical recurrence in men who underwent radical prostatectomy. The primary objective of this trial is to investigate whether hypofractionated radiotherapy improves biochemical control compared with conventionally fractionated radiotherapy. In addition, treatment-related toxicity, quality of life, and survival will be evaluated as secondary endpoints.In this prospective, randomized, multi-institutional trial (the SHARE study), patients with intermediate- or high-risk prostate cancer will be randomized to receive either hypofractionated radiotherapy (65 Gy in 2.5-Gy fractions) or conventionally fractionated radiotherapy (66 Gy in 2-Gy fractions). Prostate bed irradiation or elective pelvic nodal irradiation including the prostate bed will be performed using intensity-modulated radiotherapy and daily image guidance. Treatment efficacy will be assessed using the serum tumor marker prostate-specific antigen, and toxicity will be evaluated through both physician- and patient-reported outcomes. Quality of life will also be investigated.This study is designed to demonstrate whether hypofractionated radiotherapy is beneficial in terms of biochemical control and toxicity compared with standard salvage radiotherapy. If hypofractionated radiotherapy is shown to be superior to conventionally fractionated radiotherapy, it will mean that improved biochemical control can be achieved, accompanied by greater patient convenience and more efficient use of medical resources.ClinicalTrials.gov NCT03920033. Registered on 18 April 2019." @default.
• W3206479551 created "2021-10-25" @default.
• W3206479551 creator A5035052771 @default.
• W3206479551 creator A5035547791 @default.
• W3206479551 creator A5063259268 @default.
• W3206479551 creator A5064707258 @default.
• W3206479551 creator A5079540101 @default.
• W3206479551 creator A5083728536 @default.
• W3206479551 date "2021-10-21" @default.
• W3206479551 modified "2023-09-24" @default.
• W3206479551 title "Salvage hypofractionated accelerated versus standard radiotherapy for the treatment of biochemical recurrence after radical prostatectomy (SHARE): the protocol of a prospective, randomized, open-label, superiority, multi-institutional trial" @default.
• W3206479551 cites W1967043196 @default.
• W3206479551 cites W1970324515 @default.
• W3206479551 cites W1977970364 @default.
• W3206479551 cites W1980601718 @default.
• W3206479551 cites W1983228790 @default.
• W3206479551 cites W1996809772 @default.
• W3206479551 cites W2036220888 @default.
• W3206479551 cites W2053690746 @default.
• W3206479551 cites W2065120151 @default.
• W3206479551 cites W2099955473 @default.
• W3206479551 cites W2100010944 @default.
• W3206479551 cites W2104631398 @default.
• W3206479551 cites W2104870101 @default.
• W3206479551 cites W2107671263 @default.
• W3206479551 cites W2118742901 @default.
• W3206479551 cites W2129299671 @default.
• W3206479551 cites W2130514725 @default.
• W3206479551 cites W2131398800 @default.
• W3206479551 cites W2151660174 @default.
• W3206479551 cites W2151674154 @default.
• W3206479551 cites W2251776509 @default.
• W3206479551 cites W2278230463 @default.
• W3206479551 cites W2346061096 @default.
• W3206479551 cites W2465092116 @default.
• W3206479551 cites W2469323349 @default.
• W3206479551 cites W2515724766 @default.
• W3206479551 cites W2552100324 @default.
• W3206479551 cites W2585109238 @default.
• W3206479551 cites W2601353955 @default.
• W3206479551 cites W2603384438 @default.
• W3206479551 cites W2766039492 @default.
• W3206479551 cites W2791322512 @default.
• W3206479551 cites W2793533817 @default.
• W3206479551 cites W2885658755 @default.
• W3206479551 cites W2887443000 @default.
• W3206479551 cites W2898325713 @default.
• W3206479551 cites W2901886450 @default.
• W3206479551 cites W2943710987 @default.
• W3206479551 cites W2952808064 @default.
• W3206479551 cites W2981066984 @default.
• W3206479551 doi "https://doi.org/10.1186/s13063-021-05708-5" @default.
• W3206479551 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8532339" @default.
• W3206479551 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34674739" @default.
• W3206479551 hasPublicationYear "2021" @default.
• W3206479551 type Work @default.
• W3206479551 sameAs 3206479551 @default.
• W3206479551 citedByCount "1" @default.
• W3206479551 countsByYear W32064795512023 @default.
• W3206479551 crossrefType "journal-article" @default.
• W3206479551 hasAuthorship W3206479551A5035052771 @default.
• W3206479551 hasAuthorship W3206479551A5035547791 @default.
• W3206479551 hasAuthorship W3206479551A5063259268 @default.
• W3206479551 hasAuthorship W3206479551A5064707258 @default.
• W3206479551 hasAuthorship W3206479551A5079540101 @default.
• W3206479551 hasAuthorship W3206479551A5083728536 @default.
• W3206479551 hasBestOaLocation W32064795511 @default.
• W3206479551 hasConcept C121608353 @default.
• W3206479551 hasConcept C126322002 @default.
• W3206479551 hasConcept C126894567 @default.
• W3206479551 hasConcept C143998085 @default.
• W3206479551 hasConcept C168563851 @default.
• W3206479551 hasConcept C203092338 @default.
• W3206479551 hasConcept C2776235491 @default.
• W3206479551 hasConcept C2776694085 @default.
• W3206479551 hasConcept C2779466945 @default.
• W3206479551 hasConcept C2780192828 @default.
• W3206479551 hasConcept C2780775027 @default.
• W3206479551 hasConcept C509974204 @default.
• W3206479551 hasConcept C71924100 @default.
• W3206479551 hasConceptScore W3206479551C121608353 @default.
• W3206479551 hasConceptScore W3206479551C126322002 @default.
• W3206479551 hasConceptScore W3206479551C126894567 @default.
• W3206479551 hasConceptScore W3206479551C143998085 @default.
• W3206479551 hasConceptScore W3206479551C168563851 @default.
• W3206479551 hasConceptScore W3206479551C203092338 @default.
• W3206479551 hasConceptScore W3206479551C2776235491 @default.
• W3206479551 hasConceptScore W3206479551C2776694085 @default.
• W3206479551 hasConceptScore W3206479551C2779466945 @default.
• W3206479551 hasConceptScore W3206479551C2780192828 @default.
• W3206479551 hasConceptScore W3206479551C2780775027 @default.
• W3206479551 hasConceptScore W3206479551C509974204 @default.
• W3206479551 hasConceptScore W3206479551C71924100 @default.
• W3206479551 hasFunder F4320323011 @default.
• W3206479551 hasIssue "1" @default.
• W3206479551 hasLocation W32064795511 @default.
• W3206479551 hasLocation W32064795512 @default.
• W3206479551 hasLocation W32064795513 @default.
• W3206479551 hasLocation W32064795514 @default.
• W3206479551 hasLocation W32064795515 @default.

• next